« Back
Home /
PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM421TP)

PE-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM421TP)

Item no.	MHC-HM421TP-100UG
Manufacturer	KactusBio
Amount	100 ug
Quantity options	100 ug 500 ug
Category	Oncology By Cell Type Blastoma Carcinoma Glioma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Peptides & Proteins Recombinant Proteins Cell Biology Adenocarcinoma Cytoskeleton Myelofibrosis Mesothelioma Astrocytoma By Organ Lung Cancer Colorectal Cancer Heart & Blood Cancer small GTPases Ras Subfamily
Type	Proteins Recombinant
Format	Liquid
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	HIS, Avi
Formula	Supplied as 0.22μm filtered solution in PBS, 0.2% BSA (pH 7.4).
Dry ice	Yes
Sequence	Gly25-Thr305 (HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
NCBI	VVVGAVGVGK
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	MHC,KRAS,K-Ras 2,KRAS2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KRAS1,KRAS2,NS,NS3,RASK2,GTPase Kras,KI-RAS,RALD
Shipping Condition	Dry ice
Available
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK)
Manufacturer - Conjugate / Tag	C-His-Avi
Shipping Temperature	Shipped with dry ice.
Storage Conditions	Valid for 6 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Description	Recombinant PE-Labeled Human HLA-A11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-labeled Human HLA-A11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is assembled by biotinylated monomer and PE-Labeled streptavidin.; It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.
Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Supplied as 0.22 μm filtered solution in PBS, 0.2% BSA (pH 7.4).
Biotinylated	no

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

MHC-HM421TP-100UG-datasheet.pdf

MHC-HM421TP-100UG-safety-datasheet.pdf